Nipro (8086) AI Stock Analysis

• Market Cap: €250.92B
• Dividend Yield: 2.08%
• Average Volume (3M): 554.43K
• Price to Earnings (P/E): 44.0
• Beta (1Y): 0.42
• Revenue Growth: 8.83%
• EPS Growth: -40.24%
• Country: JP
• Employees: 38,117
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 20.06
• Shares Outstanding: 171,459,470
• 10 Day Avg. Volume: 466,300
• 30 Day Avg. Volume: 554,433
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €1,323.84
• Price Target Upside: -13.95% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 57 Neutral
• Price Target: ¥1,324.00 ▼(-13.94% Downside)

The overall score reflects solid revenue growth and strong operating cash flow, offset by challenges in profitability, high leverage, and an overvalued stock price. The technical analysis suggests a bearish trend, reinforcing a cautious outlook.

Nipro Business Overview & Revenue Model

Company Description

Nipro Corporation, together with its subsidiaries, engages in the medical devices, pharmaceuticals, and pharma packaging businesses. The company's Medical Device business develops, manufactures, and sells various disposable medical products comprising renal, intervention and anesthesiology, injection and infusion, dialysis, cardiopulmonary, diabetic, and cell cultures products; and sells artificial organ-related products, and generic and kit products. Its Pharmaceutical business provides pharmaceutical combination products, including dual chamber bags, pre-filled syringes, and half-type kits; and contract manufacturing services for orally administered drugs, injectables, and external preparations. The company's Pharma Packaging business offers glass vials, ampoules, syringes, and cartridges; glass tubes; glass forming machinery; glass bulbs for vacuum flasks; and other parts of pharmaceutical packaging, such as rubber plugs. Its Other business provides thermostable enzymes for clinical chemistry. The company also offers business management services. Nipro Corporation serves customers in Japan, the Americas, Europe, and rest of Asia. The company was founded in 1947 and is headquartered in Osaka, Japan.

How the Company Makes Money

Nipro Corporation generates revenue through its diverse portfolio of products and services across three main segments: medical devices, pharmaceuticals, and pharma packaging. The medical devices segment includes the production and sale of dialysis machines, blood glucose monitoring systems, and other medical equipment. The pharmaceuticals segment involves the manufacturing and distribution of generic drugs and other pharmaceutical products. The pharma packaging segment provides packaging solutions for pharmaceutical products. Nipro's revenue is further supported by strategic partnerships and collaborations with healthcare institutions and other companies in the medical and pharmaceutical industries, enhancing its market reach and product offerings.

Nipro Financial Statement Overview

Summary

Nipro shows solid revenue growth and stable gross margins, but faces challenges in net profitability and high leverage. While operating cash flow is healthy, negative free cash flow indicates a need for improved capital management.

Income Statement

Nipro has demonstrated consistent revenue growth with a notable increase of 9.83% from 2024 to 2025. Gross profit margins have remained stable, reflecting strong cost management. However, the net profit margin has decreased due to a significant drop in net income, highlighting potential challenges in managing operating expenses or increased costs elsewhere.

Balance Sheet

The company's debt-to-equity ratio indicates high leverage, which could pose risks in economic downturns. Although total assets have increased, stockholder equity growth has not kept pace, resulting in a moderate equity ratio. Return on equity is low, suggesting challenges in generating efficient returns for shareholders.

Cash Flow

Nipro's free cash flow has shown improvement but remains negative, indicating ongoing challenges in generating surplus cash after capital expenditures. The operating cash flow to net income ratio is strong, suggesting that the company generates healthy operating cash relative to earnings, despite reduced net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	644.59B	644.59B	586.78B	545.20B	494.79B	455.56B
Gross Profit	190.88B	190.88B	171.32B	163.45B	149.27B	138.84B
EBITDA	92.58B	92.58B	84.62B	70.02B	73.54B	64.88B
Net Income	5.11B	5.11B	11.11B	4.57B	13.46B	14.21B
Balance Sheet
Total Assets	1.17T	1.18T	1.11T	1.03T	930.32B	854.40B
Cash, Cash Equivalents and Short-Term Investments	106.67B	106.67B	99.67B	89.68B	95.34B	90.27B
Total Debt	632.07B	632.07B	635.69B	605.93B	564.85B	545.28B
Total Liabilities	858.94B	864.77B	840.03B	785.23B	730.46B	680.35B
Stockholders Equity	252.45B	252.45B	232.66B	206.32B	185.24B	161.02B
Cash Flow
Free Cash Flow	0.00	-8.15B	-21.33B	-74.44B	-11.59B	14.91B
Operating Cash Flow	0.00	68.46B	72.94B	10.39B	68.21B	66.09B
Investing Cash Flow	0.00	-71.88B	-87.08B	-71.74B	-78.43B	-45.07B
Financing Cash Flow	0.00	5.38B	22.14B	43.08B	10.30B	-22.06B

Nipro Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1538.50
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:8086, the sentiment is Positive. The current price of 1538.5 is above the 20-day moving average (MA) of 1533.57, above the 50-day MA of 1446.68, and above the 200-day MA of 1364.07, indicating a bullish trend. The MACD of 31.75 indicates Positive momentum. The RSI at 60.17 is Neutral, neither overbought nor oversold. The STOCH value of 51.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:8086.

Nipro Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
7747	73 Outperform	718.45B	56.54	8.46%	0.92%	11.60%	-19.38%
7716	73 Outperform	177.22B	34.45	7.08%	2.51%	10.98%	-76.45%
4543	73 Outperform	3.75T	29.82	8.55%	1.02%	7.58%	6.74%
7733	70 Outperform	2.10T	18.97	15.32%	1.07%	0.59%	557.87%
6869	67 Neutral	1.18T	24.91	11.57%	1.58%	5.09%	-9.10%
8086	57 Neutral	€250.92B	44.05	2.49%	2.08%	8.83%	-40.24%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Nipro Corporate Events

Nipro Corporation Announces Q1 2025 Financial Results with Mixed Performance

Nipro Corporation reported its consolidated financial results for the three months ended June 30, 2025, showing a 4.5% increase in net sales and a 24.6% rise in operating profit compared to the previous year. Despite these gains, the company experienced a significant decline in ordinary profit by 45.2%, reflecting challenges in its operations. The financial forecast for the fiscal year ending March 31, 2026, anticipates continued growth in net sales and operating profit, indicating a positive outlook for stakeholders.

Nipro Corporation Transfers Real Estate Interest for Financial Gain

Nipro Corporation has announced the transfer of beneficial interest in a domestic real estate trust, specifically land located in Hamura, Tokyo, to Hulic Co., Ltd. This strategic move aims to enhance asset efficiency and strengthen Nipro’s financial base, resulting in an extraordinary gain of ¥4.1 billion. The property will continue to be utilized under a lease agreement, ensuring no disruption to Nipro’s operations. The transaction is expected to positively impact Nipro’s financial performance in the fiscal year ending March 2026, with potential revisions to be disclosed as necessary.

Nipro Corporation Proposes Amendments to Strengthen Governance

Nipro Corporation’s Board of Directors has proposed amendments to its Articles of Incorporation, aiming to enhance corporate governance and operational flexibility. Key changes include revising the Board’s operational procedures, clarifying director roles, increasing the number of Audit & Supervisory Board members, and allowing the Board to make decisions on surplus dividends. These amendments are expected to strengthen Nipro’s governance framework and improve management efficiency, potentially impacting stakeholders positively by fostering a more agile and responsive corporate structure.